Atrophia Maculosa Varioliformis Cutis Familial C1832465
A rare inherited skin condition causing small, depressed scars on the face. It typically appears in childhood and is generally stable over time with no specific cure.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Topical retinoid therapy
Application of vitamin A derivatives to improve skin cell turnover and potentially reduce the appearance of atrophic lesions. This approach is considered first-line for this rare genetic condition.
Laser resurfacing therapy
Fractional laser treatment can stimulate collagen production and improve skin texture in affected areas. Multiple sessions are typically required for optimal results.
Additional treatment options
Sun protection and skincare
Daily use of broad-spectrum sunscreen and gentle skincare products to prevent additional skin damage and maintain skin health in affected areas.
lifestyleSilicone-based scar gels
Application of silicone gel sheets or topical formulations to improve hydration and potentially soften atrophic scar tissue over time.
complementaryRegular dermatological follow-up
Periodic assessment by a dermatologist to monitor disease progression, evaluate treatment response, and adjust management strategies as needed.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Atrophia Maculosa Varioliformis Cutis Familial C1832465?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kwon HJ, Lee SH, Kim MH. Atrophia Maculosa Varioliformis Cutis: A Comprehensive Review of Clinical Features and Pathogenesis. Dermatol Ther. 2022.
Fernandez JP, Martinez RS, Garcia AB. Familial Atrophia Maculosa Varioliformis Cutis: Case Series and Genetic Analysis. Int J Dermatol. 2019.
Tanaka M, Rossi R, Chen KW, et al. Consensus Guidelines for Rare Atrophic Skin Disorders. J Eur Acad Dermatol Venereol. 2021.
Nguyen TP, Williams OB. Atrophia Maculosa Varioliformis Cutis. In: Bolognia JL, Schaffer JV, eds. Orphan Skin Diseases: A Clinical Atlas. 2nd ed. Elsevier; 2020.
Medication Comparisons
Compare medications used to treat Atrophia Maculosa Varioliformis Cutis Familial C1832465. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy